- |||||||||| 2-bromo-D-lysergic acid diethylamide (NYPRG-101) / Ceruvia Lifesci
Journal: A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies. (Pubmed Central) - Jan 13, 2025
In the presented paper, an UHPLC-QqQ-MS/MS method was developed for trace determination (fg mL-1) of LSD, its designer analogs (ALD-52, AL-LAD, LAMPA, LSM-775, LSZ, MiPLA, 1B-LSD, 1cP-LSD, 1cP-MiPLA, 1P-LSD, 1P-MiPLA, 1V-LSD and 2-Bromo-LSD) and its metabolite (2-oxo-3-OH-LSD) with simultaneous separation of structural isomers...The presented method is the most sensitive to date for analyzing designer LSD analogs in biological samples, with potential for routine clinical and forensic use, enhancing detection of emerging illicit compounds. By examining the mass spectra (QTOF-MS/MS) obtained in this study and reviewing the literature on analytical characterization of LSD analogs, we proposed fragmentation patterns to aid in future identification of new designer LSD analogs (NPS).
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion: Psilocybin for the Treatment of Cluster Headache (clinicaltrials.gov) - Dec 15, 2023
P1, N=25, Completed,
By examining the mass spectra (QTOF-MS/MS) obtained in this study and reviewing the literature on analytical characterization of LSD analogs, we proposed fragmentation patterns to aid in future identification of new designer LSD analogs (NPS). Active, not recruiting --> Completed
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion date, Trial primary completion date: Psilocybin for the Treatment of Cluster Headache (clinicaltrials.gov) - Jun 15, 2023
P1, N=24, Active, not recruiting,
These data will help in the fields of clinical application and targeted drug discovery. Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2022
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion, Enrollment change: Psilocybin for the Treatment of Migraine Headache (clinicaltrials.gov) - Jun 15, 2023
P1, N=14, Completed,
Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2022 Active, not recruiting --> Completed | N=24 --> 14
- |||||||||| 2-bromo-D-lysergic acid diethylamide (NYPRG-101) / Ceruvia Lifesci
A non-hallucinogenic LSD analogue with therapeutic potential in mood disorders (Montreal Bonaventure Hotel (CAN meeting headquarters)) - Jun 10, 2023 - Abstract #CANACN2023CAN_ACN_504;
2-Bromo-LSD (2-Br-LSD/BETR-001) is an LSD derivative with 5-HT2A partial agonist activity that lacks hallucinogenic effects...Our findings demonstrate that 2-Br-LSD induces cortical plasticity in vitro and in vivo, promotes active stress-coping behaviours, and reveres the behavioural effects of chronic stress. These results show that 2-Br-LSD possesses therapeutic potential and represents a promising alternative to classic psychedelics in treating depression.
- |||||||||| 2-bromo-D-lysergic acid diethylamide (NYPRG-101) / Ceruvia Lifesci
A Non-Hallucinogenic LSD Analogue With Therapeutic Potential in Mood Disorders (Sapphire AB) - Apr 29, 2023 - Abstract #SOBP2023SOBP_838;
2-Bromo-LSD (2-Br-LSD/BETR-001) is an LSD derivative with 5-HT2A partial agonist activity that lacks hallucinogenic effects...Conclusions Our findings demonstrate that 2-Br-LSD induces cortical plasticity in vitro and in vivo, promotes active stress-coping behaviours, and reveres the behavioural effects of chronic stress. These results show that 2-Br-LSD possesses therapeutic potential and represents a promising alternative to classic psychedelics in treating depression.
- |||||||||| 2-bromo-D-lysergic acid diethylamide (NYPRG-101) / Ceruvia Lifesci, BETR-001 / BetterLife Pharma
Journal: A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. (Pubmed Central) - Apr 3, 2023
2-Br-LSD also reverses the behavioral effects of chronic stress. Overall, 2-Br-LSD has an improved pharmacological profile compared with LSD and may have profound therapeutic value for mood disorders and other indications.
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion date, Trial primary completion date: Psilocybin for the Treatment of Migraine Headache (clinicaltrials.gov) - Jan 26, 2023
P1, N=24, Active, not recruiting,
Overall, 2-Br-LSD has an improved pharmacological profile compared with LSD and may have profound therapeutic value for mood disorders and other indications. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| 2-bromo-D-lysergic acid diethylamide (NYPRG-101) / Ceruvia Lifesci
A Non-Hallucinogenic LSD Analog With Therapeutic Potential for Mood Disorders (Grand Saguaro) - Oct 31, 2022 - Abstract #ACNP2022ACNP_1138;
Our findings demonstrate that 2-Br-LSD induces structural plasticity in cortical neurons in vitro and in vivo, promotes active stress-coping behaviours and reverses the behavioural effects of CVS. These results show that 2-Br-LSD may possess a therapeutic potential and represents a promising alternative to psychedelics in treating MDD.
- |||||||||| 2-bromo-D-lysergic acid diethylamide (NYPRG-101) / Ceruvia Lifesci, Dopergin (lisuride) / Bayer
Investigation of the Pharmacological Properties of 2-Br-LSD, a Non-Hallucinogenic LSD Analog (Grand Saguaro) - Oct 31, 2022 - Abstract #ACNP2022ACNP_992;
2-Br-LSD appears to act as a non-hallucinogenic 5-HT2A agonist, similar to the isolysergic acid derivative lisuride. Our studies provide insight into the non-hallucinogenic activity of 2-Br-LSD, which is probably a consequence of its weak partial agonist activity at the 5-HT2A receptor.
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion date, Trial primary completion date: Psilocybin for the Treatment of Cluster Headache (clinicaltrials.gov) - Jul 28, 2022
P1, N=24, Active, not recruiting,
Our studies provide insight into the non-hallucinogenic activity of 2-Br-LSD, which is probably a consequence of its weak partial agonist activity at the 5-HT2A receptor. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion date, Trial primary completion date: Psilocybin for the Treatment of Migraine Headache (clinicaltrials.gov) - Feb 25, 2022
P1, N=24, Active, not recruiting,
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Mar 2020 --> Dec 2022
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Enrollment closed: Psilocybin for the Treatment of Cluster Headache (clinicaltrials.gov) - Sep 13, 2021
P1, N=24, Active, not recruiting,
Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Mar 2020 --> Dec 2022 Recruiting --> Active, not recruiting
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion date, Trial primary completion date: Psilocybin for the Treatment of Cluster Headache (clinicaltrials.gov) - Aug 18, 2021
P1, N=24, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Nov 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial primary completion date: Psilocybin for the Treatment of Cluster Headache (clinicaltrials.gov) - Jan 8, 2021
P1, N=24, Recruiting,
Trial completion date: Nov 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Trial primary completion date: Dec 2020 --> Jun 2021
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion date: Psilocybin for the Treatment of Migraine Headache (clinicaltrials.gov) - Jan 7, 2021
P1, N=24, Active, not recruiting,
Trial primary completion date: Dec 2020 --> Jun 2021 Trial completion date: Oct 2020 --> Oct 2021
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial primary completion date: Psilocybin for the Treatment of Cluster Headache (clinicaltrials.gov) - Aug 8, 2020
P1, N=24, Recruiting,
Trial completion date: Oct 2020 --> Oct 2021 Trial primary completion date: Jun 2020 --> Dec 2020
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion date: Psilocybin for the Treatment of Migraine Headache (clinicaltrials.gov) - Jul 24, 2020
P1, N=24, Active, not recruiting,
Trial primary completion date: Jun 2020 --> Dec 2020 Trial completion date: Jun 2020 --> Oct 2020
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Enrollment closed: Psilocybin for the Treatment of Migraine Headache (clinicaltrials.gov) - Jan 28, 2020
P1, N=24, Active, not recruiting,
Trial completion date: Jun 2020 --> Oct 2020 Recruiting --> Active, not recruiting
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial completion date, Trial primary completion date: Psilocybin for the Treatment of Migraine Headache (clinicaltrials.gov) - Dec 18, 2019
P1, N=24, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Nov 2019 --> Jun 2020
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Trial primary completion date: Psilocybin for the Treatment of Cluster Headache (clinicaltrials.gov) - Dec 18, 2019
P1, N=24, Recruiting,
Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Nov 2019 --> Jun 2020 Trial primary completion date: Nov 2019 --> Jun 2020
- |||||||||| psilocybin (SYNP-101) / Ceruvia Lifesci
Phase classification: Psilocybin for the Treatment of Migraine Headache (clinicaltrials.gov) - Feb 4, 2019
P1, N=24, Recruiting,
Trial primary completion date: Nov 2019 --> Jun 2020 Phase classification: P2 --> P1
|
